BusinessCURE Pharmaceutical Launches New Brand Focused on Patient Needs in Medication DeliveryBy Nasdaq OMXJan 4, 2018, 2:01 PM UTC
BusinessCure Pharmaceutical Enters Into Product Development Agreement with Therapix Biosciences To Develop Cannabinoid-Based Product For Sleep DisordersBy Nasdaq OMXNov 7, 2017, 2:00 PM UTC
BusinessOak Therapeutics Announces Results of Bioequivalence Study of Company’s Oral Dissolvable Strip for TuberculosisBy Nasdaq OMXOct 3, 2017, 1:00 PM UTC
BusinessCURE Pharmaceutical Launches New Academic Partnership Program Providing the Company’s Proprietary CureFilm™ for More Humane and Effective Animal ResearchBy Nasdaq OMXSep 6, 2017, 1:00 PM UTC
BusinessCURE Pharmaceutical to Participate in Panel Discussion on the Future of Clinical Research using Cannabis at The Cannabis Science Conference in Portland, ORBy Nasdaq OMXAug 29, 2017, 1:01 PM UTC
BusinessCURE Pharmaceutical Subsidiary, Oak Therapeutics, Completes Critical Milestone in Phase 1 of NIH Grant to Develop Oral Dissolvable Strip for TuberculosisBy Nasdaq OMXAug 22, 2017, 3:19 PM UTC
BusinessCURE Pharmaceutical Expects Increased Demand for Its Enhanced Transdermal Drug Delivery PlatformBy Nasdaq OMXJul 5, 2017, 1:00 PM UTC
